Company intelligence / Profile preview

Adcentrx Therapeutics

San Diego, California, United Statesadcentrx.com ↗

Ownership: Private
Development stage: Other

Overview

Adcentrx has two clinical-stage ADCs in Phase 1 trials. ADRX-0706 (Nectin-4 ADC) has shown a differentiated safety and pharmacokinetic profile with lower incidence of adverse events like peripheral neuropathy, and preliminary efficacy signals across different dose levels and tumor types. ADRX-0405 (STEAP1 ADC) began Phase 1 dosing in January 2025 with initial results expected in Q4 2025.

Therapeutic areas: Oncology
Modalities: Antibody-Drug Conjugates (ADCs)Protein Conjugate Therapeutics
Industry: Biotech

Drug pipeline

6 assets

ADRX-0706

5 more assets in the full pipeline.

Partnerships

Shanghai Defeng Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on Adcentrx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adcentrx Therapeutics.